Novel DREADD actuator for the first peripherally restricted DREADD system named the HCAD DREADD system. This system enables precise study of peripheral physiology without CNS interference.
Â
Unlike other DREADD ligands (e.g. CNO & DCZ), FCH-2296413 does not cross the BBB so is able to selectively activate the peripherally restricted HCAD Gi-DREADD. To date, relatively few DREADD studies have been conducted in the PNS.
Â
FCH-2296413 has excellent drug-like properties, peripherally restricted pharmacokinetics and clean off-target profiles. The HCAD system has been shown to selectively reduce pain in mice by targeting peripheral tissues of dorsal root ganglion (DRG). Active in-vivo. FCH-2296413 is a racemic mixture which includes the racemates AR2599088 ('088) and AR259089 ('089).
Solubility & Handling
Storage instructions
-20°C
Solubility overview
Soluble in DMSO (100mM)
Important
This product is for RESEARCH USE ONLY and is not intended for therapeutic or diagnostic use. Not for human or veterinary use